Klaus Mendla
Consultant / Advisor bij Angelini Ventures SpA
Profiel
Klaus Mendla acts as an external business development consultant to Angelini Ventures.
He is a life sciences professional with strong scientific background and proven track record in Pharma business development in the field of Central Nervous System (CNS) diseases.
Prior to joining Angelini, Klaus was Global Head of Business Development & Licensing CNS at Boehringer Ingelheim (BI), with worldwide responsibility for all Pharma partnering activities in the company’s therapeutic area CNS diseases.
In this role, Klaus took the lead on developing and implementing BI’s strategy for partnering in the neurology and neuropsychiatry space.
He and his team successfully concluded numerous research collaboration and licensing agreements with Pharma and Biotech companies, with a total deal value in the multi-billion-Euro range.
Before joining BI’s global business development and licensing organization, Klaus was director of Molecular Biology and Neurodegenerative Diseases Research at BI, where he led drug discovery teams focused on novel treatments for Alzheimer’s disease and other neurodegenerative disorders.
Klaus received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship at the University of Heidelberg on the pathophysiology of lysosomal storage diseases.
Actieve functies van Klaus Mendla
Bedrijven | Functie | Begin |
---|---|---|
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Consultant / Advisor | - |
Eerdere bekende functies van Klaus Mendla
Bedrijven | Functie | Einde |
---|---|---|
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Italia SpA Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Italia SpA engages in the research and development of pharmaceutical drugs for cardiovascular, respiratory and virological diseases. It operates through the following business divisions: prescription and hospital drugs; products for self-medication and well-being; and veterinary medicine. The company was founded in 1972 and is headquartered in Milan, Italy. | Corporate Officer/Principal | - |
Opleiding van Klaus Mendla
University of Münster | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Finance |
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Italia SpA Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Italia SpA engages in the research and development of pharmaceutical drugs for cardiovascular, respiratory and virological diseases. It operates through the following business divisions: prescription and hospital drugs; products for self-medication and well-being; and veterinary medicine. The company was founded in 1972 and is headquartered in Milan, Italy. | Health Technology |